NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday first-quarter revenue grown of 13 percent driven by a sharp uptick in assay revenues.

The Austin, Texas-based molecular diagnostics developer reported total revenues of $48.7 million for the quarter ended March 31, compared to revenues of $43.3 million for the first quarter of 2011. It beat Wall Street's consensus estimate of $48.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.